R&D Insights: How Corcept Therapeutics Incorporated and ImmunityBio, Inc. Allocate Funds

Biotech Giants' R&D Spending: A Decade of Growth

__timestampCorcept Therapeutics IncorporatedImmunityBio, Inc.
Wednesday, January 1, 2014183720001595000
Thursday, January 1, 20151541900011434000
Friday, January 1, 20162384400026546000
Sunday, January 1, 20174037600039778000
Monday, January 1, 20187524700053418000
Tuesday, January 1, 201989017000111997000
Wednesday, January 1, 2020114764000139507000
Friday, January 1, 2021113864000195958000
Saturday, January 1, 2022130991000248149000
Sunday, January 1, 2023184353000232366000
Loading chart...

Unleashing the power of data

R&D Spending: A Tale of Two Biotech Innovators

In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Corcept Therapeutics Incorporated and ImmunityBio, Inc. have demonstrated contrasting strategies in their R&D investments.

From 2014 to 2023, Corcept Therapeutics increased its R&D expenses by nearly 900%, starting from a modest $18 million in 2014 to a substantial $184 million in 2023. This growth reflects Corcept's strategic focus on expanding its research capabilities. Meanwhile, ImmunityBio, Inc. showcased an even more aggressive approach, with R&D spending skyrocketing from $1.6 million in 2014 to $232 million in 2023, marking an impressive 14,500% increase.

These figures highlight the dynamic nature of the biotech industry, where companies must continuously innovate to stay ahead. As these two companies forge their paths, their R&D investments will likely play a pivotal role in shaping their future successes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025